B. Riley Financial Varied
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.840 -0.070 (-1.43%)
Streaming Delayed Price Updated: 10:25 AM EDT, Sep 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,380,748
Open 4.850
Bid (Size) 4.840 (61)
Ask (Size) 4.850 (64)
Prev. Close 4.910
Today's Range 4.790 - 4.880
52wk Range 3.790 - 12.36
Shares Outstanding 168,425,907
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nvidia Has Invested in These 6 Companies. Should You Follow Suit?
The world's most valuable company holds stakes in a number of smaller tech players. 
Via The Motley Fool
Topics Artificial Intelligence
Where Will Recursion Pharmaceuticals Be in 5 Years?
Could investing in this stock be an underrated way to profit from the rapidly expanding AI industry? 
Via The Motley Fool
Topics Animal Testing Artificial Intelligence

Performance

YTD
-32.9%
-32.9%
1 Month
+3.9%
+3.9%
3 Month
-4.3%
-4.3%
6 Month
-8.5%
-8.5%
1 Year
-26.6%
-26.6%

More News

Read More
The Biotech Stock That's Too Risky for Most Investors
Via The Motley Fool
Topics Artificial Intelligence
10 Hidden-Gem AI Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence
Cramer's Friday Watchlist: AI Soars as Consumer Stumbles Amidst Economic Divide
Via MarketMinute
Topics Artificial Intelligence Economy Energy
Jim Cramer Says This Financial Stock Is A 'Total Spec,' Likes Dutch Bros,
Via Benzinga
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
Via The Motley Fool
Topics Artificial Intelligence
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape
Via MarketMinute
Topics Animal Testing Artificial Intelligence Intellectual Property
Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch.
Via The Motley Fool
Topics Artificial Intelligence
What Analysts Are Saying About Recursion Pharmaceuticals Stock
Via Benzinga
When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts
Via The Motley Fool
Topics Artificial Intelligence ETFs Regulatory Compliance
3 AI Stocks Disrupting Trillion-Dollar Industries
Via The Motley Fool
Topics Artificial Intelligence Economy
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Topics Artificial Intelligence
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
Via The Motley Fool
Topics Artificial Intelligence
Why Recursion Pharmaceuticals Stock Caught a Cold This Week
Via The Motley Fool
Topics Regulatory Compliance
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
Via FinancialNewsMedia
Topics Artificial Intelligence
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Via The Motley Fool
Topics Artificial Intelligence
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
Via The Motley Fool
Recursion (RXRX) Q2 Revenue Jumps 33%
Via The Motley Fool
Topics Artificial Intelligence
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates
Via Benzinga
Recursion Pharmaceuticals-A (NASDAQ:RXRX) Reports Mixed Q2 2025 Earnings: Revenue Beat but EPS Miss
Via Chartmill

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 4.840
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 09/30/25 10:25 AM ET
What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 815.18M
How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Recursion Pharmaceuticals, Inc. - Class A Common Stock has 815M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.